RAPT Therapeutics, Inc. (RAPT) Misses Q2 EPS by 56c

RAPT Therapeutics, Inc. (NASDAQ: RAPT) reported Q2 EPS of ($0.65), $0.56 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on RAPT Therapeutics, Inc. (RAPT) click here.

You May Also Be Interested In

• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
• Citi Upgrades Zhejiang Dahua Technology (002236:CH) to Neutral
• ICICI Securities Downgrades Manappuram Finance Ltd (MGFL:IN) to Hold (3)